BIIB
Price
$128.00
Change
+$0.25 (+0.20%)
Updated
Aug 11, 04:59 PM (EDT)
Capitalization
19.16B
72 days until earnings call
JNJ
Price
$173.81
Change
+$0.48 (+0.28%)
Updated
Aug 11, 04:12 PM (EDT)
Capitalization
417.44B
71 days until earnings call
Interact to see
Advertisement

BIIB vs JNJ

Header iconBIIB vs JNJ Comparison
Open Charts BIIB vs JNJBanner chart's image
Biogen
Price$128.00
Change+$0.25 (+0.20%)
Volume$14.37K
Capitalization19.16B
Johnson & Johnson
Price$173.81
Change+$0.48 (+0.28%)
Volume$8.61K
Capitalization417.44B
BIIB vs JNJ Comparison Chart in %
Loading...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
JNJ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BIIB vs. JNJ commentary
Aug 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a Hold and JNJ is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 12, 2025
Stock price -- (BIIB: $127.75 vs. JNJ: $173.33)
Brand notoriety: BIIB and JNJ are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BIIB: 0% vs. JNJ: 92%
Market capitalization -- BIIB: $19.16B vs. JNJ: $417.44B
BIIB [@Pharmaceuticals: Major] is valued at $19.16B. JNJ’s [@Pharmaceuticals: Major] market capitalization is $417.44B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $560.87B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $85.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIIB’s FA Score shows that 0 FA rating(s) are green whileJNJ’s FA Score has 4 green FA rating(s).

  • BIIB’s FA Score: 0 green, 5 red.
  • JNJ’s FA Score: 4 green, 1 red.
According to our system of comparison, JNJ is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIIB’s TA Score shows that 2 TA indicator(s) are bullish while JNJ’s TA Score has 4 bullish TA indicator(s).

  • BIIB’s TA Score: 2 bullish, 6 bearish.
  • JNJ’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, JNJ is a better buy in the short-term than BIIB.

Price Growth

BIIB (@Pharmaceuticals: Major) experienced а -3.18% price change this week, while JNJ (@Pharmaceuticals: Major) price change was +3.59% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.59%. For the same industry, the average monthly price growth was +4.02%, and the average quarterly price growth was +11.86%.

Reported Earning Dates

BIIB is expected to report earnings on Oct 22, 2025.

JNJ is expected to report earnings on Oct 21, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.59% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
JNJ($417B) has a higher market cap than BIIB($19.2B). JNJ has higher P/E ratio than BIIB: JNJ (18.56) vs BIIB (12.50). JNJ YTD gains are higher at: 21.847 vs. BIIB (-16.460). JNJ has higher annual earnings (EBITDA): 35.6B vs. BIIB (2.79B). JNJ has more cash in the bank: 18.9B vs. BIIB (2.76B). BIIB has less debt than JNJ: BIIB (6.6B) vs JNJ (50.8B). JNJ has higher revenues than BIIB: JNJ (90.6B) vs BIIB (10B).
BIIBJNJBIIB / JNJ
Capitalization19.2B417B5%
EBITDA2.79B35.6B8%
Gain YTD-16.46021.847-75%
P/E Ratio12.5018.5667%
Revenue10B90.6B11%
Total Cash2.76B18.9B15%
Total Debt6.6B50.8B13%
FUNDAMENTALS RATINGS
BIIB vs JNJ: Fundamental Ratings
BIIB
JNJ
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
16
Undervalued
PROFIT vs RISK RATING
1..100
10031
SMR RATING
1..100
7332
PRICE GROWTH RATING
1..100
6122
P/E GROWTH RATING
1..100
9480
SEASONALITY SCORE
1..100
8555

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

JNJ's Valuation (16) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (90) in the Biotechnology industry. This means that JNJ’s stock grew significantly faster than BIIB’s over the last 12 months.

JNJ's Profit vs Risk Rating (31) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (100) in the Biotechnology industry. This means that JNJ’s stock grew significantly faster than BIIB’s over the last 12 months.

JNJ's SMR Rating (32) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (73) in the Biotechnology industry. This means that JNJ’s stock grew somewhat faster than BIIB’s over the last 12 months.

JNJ's Price Growth Rating (22) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (61) in the Biotechnology industry. This means that JNJ’s stock grew somewhat faster than BIIB’s over the last 12 months.

JNJ's P/E Growth Rating (80) in the Pharmaceuticals Major industry is in the same range as BIIB (94) in the Biotechnology industry. This means that JNJ’s stock grew similarly to BIIB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIIBJNJ
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
28%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
77%
Bearish Trend 4 days ago
44%
Momentum
ODDS (%)
Bearish Trend 4 days ago
68%
N/A
MACD
ODDS (%)
Bearish Trend 4 days ago
70%
N/A
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
71%
Bullish Trend 4 days ago
40%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
70%
Bullish Trend 4 days ago
40%
Advances
ODDS (%)
Bullish Trend 11 days ago
53%
Bullish Trend 4 days ago
41%
Declines
ODDS (%)
Bearish Trend 13 days ago
70%
Bearish Trend 6 days ago
43%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
55%
Bearish Trend 4 days ago
52%
Aroon
ODDS (%)
N/A
Bullish Trend 4 days ago
42%
View a ticker or compare two or three
Interact to see
Advertisement
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
JNJ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AGFY25.891.59
+6.54%
Agrify Corporation
OPEN1.950.10
+5.41%
Opendoor Technologies
PBFS12.410.04
+0.32%
Pioneer Bancorp
SPKLU10.79N/A
N/A
Spark I Acquisition Corp
FSS125.39-0.76
-0.60%
Federal Signal Corp

BIIB and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with PFE. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIIB
1D Price
Change %
BIIB100%
N/A
PFE - BIIB
53%
Loosely correlated
+1.44%
MRK - BIIB
48%
Loosely correlated
+0.40%
NVS - BIIB
45%
Loosely correlated
+0.79%
GSK - BIIB
45%
Loosely correlated
+0.59%
AMGN - BIIB
44%
Loosely correlated
+1.24%
More

JNJ and

Correlation & Price change

A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with NVS. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then NVS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JNJ
1D Price
Change %
JNJ100%
+1.05%
NVS - JNJ
55%
Loosely correlated
+0.79%
GSK - JNJ
49%
Loosely correlated
+0.59%
PFE - JNJ
45%
Loosely correlated
+1.44%
BIIB - JNJ
44%
Loosely correlated
N/A
SNY - JNJ
44%
Loosely correlated
-0.63%
More